Regardless of substantial endeavor for decades, the development of effective disease‐modifying therapeutics for AD has frequently failed, making the morbidity of AD high static.[1] More than 20 compounds which are mainly based on amyloid and tau hypothesis have completed large phase 3, double‐blind, randomized control trials in cohorts of patients at various stages of AD. The gene discussed is MAPT; the disease is Alzheimer disease.